OTYŁOŚĆ - PRZYCZYNY I LECZENIE

Zofia Suchocka

doi:10.56782/pps.40

Published : 2003-08-04

Vol. 1 No. 1 (2003)

OBESITY - REASONS AND TREATMENT

Zofia Suchocka

DOI: https://doi.org/10.56782/pps.40

Abstract

Obesity is a chronic disease with a strong familial component, fostered by environment: lack of physical activity combined with high-calorie, low-cost foods. The recent increase in the incidence of obesity has been too sudden to be solely due to genetic factors. Epidemiological studies suggest that children born with poor maternal poor fetal nutrition resulted in increased rates of obesity later in life. Altered genetic expression as a consequence of an adaptation to changes during fetal development is a reason of profound adult hyperphagia. Programmed offspring also develop obesity, hyperleptynemia, hyperinsulinism and hypertension during adult life and postnatal hypercaloric nutrition amplifies the metabolic abnormalities induced by programming. Obesity and related metabolic disorders (diabetes mellitus, certain types of cancers, cardiovascular disease) have become a major health issue in modern society. Intra-abdominal fat accumulation in adult obese patients has been proposed as a risk factor for various biochemical disorders, which usually display a fatal course. Thus, the main prognostic problem in obesity is to estimate accurately the quantity and distribution of fat in the body. There are several different types of effective treatment options to manage weight including: dietary therapy, physical activity, behavior therapy, drug therapy, combined therapy and surgery. Weight loss of about 10 percent of excess body weight is proven to benefit health by reducing many obesity-related risk factors.

Keywords:

obesity, visceral obesity, pathophysiology of obesity, hyperphagia, obesity treatment

Similar Articles

Olga Grelewicz, Gabriela Kulbacka, Tomasz Mikuła, Alicja Wiercińska-Drapało, Does testosterone intake affect diagnosing primary HIV infection? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 1 (2023)
Łukasz Dobrek, Analysis of the activity of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in the field of clinical trials, registration of medicinal products and monitoring of adverse drug reactions in 2017-2021 , Prospects in Pharmaceutical Sciences: Vol. 20 No. 4 (2022)
Ewa Napiórkowska, Overview of cyclodextrins and medicinal products containing cyclodextrins currently registered in Poland , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Bartłomiej Kałaska, Joanna Mikłosz, Emilia Sokołowska, Andrzej Mogielnicki, THE PROS AND CONS OF MODERN ANTICOAGULANT THERAPY , Prospects in Pharmaceutical Sciences: Vol. 14 No. 10 (2016)
Piotr Wałejko, Stanisław Witkowski, POLYUNSATURATED FATTY ACIDS AND THEIR OXIDATION PRODUCTS , Prospects in Pharmaceutical Sciences: Vol. 14 No. 7 (2016)
Michał Gackowski, Katarzyna Połomska, Natalia Szczucka, Mateusz Wylaź, Digital-based system as a tool for improving healthcare coordination - a perspective study , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Martyna Z. Wróbel, Monika Marciniak, 5-HT1A RECEPTOR LIGANDS AS POTENTIAL ANTIDEPRESSANTS , Prospects in Pharmaceutical Sciences: Vol. 13 No. 5 (2015)
Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
Grzegorz Ślifirski, Tomasz Słowiński, Jacek Stefanowicz, NOVEL TRENDS IN ANTIPSYCHOTIC DRUG DEVELOPMENT , Prospects in Pharmaceutical Sciences: Vol. 13 No. 4 (2015)
Anna Flis-Borsuk, Lidia Śliwka, Zofia Suchocka, Jakub Borsuk, Zbigniew Fijałek, Katarzyna Lubelska, Piotr Suchocki, SELENITETRIGLYCERIDES AND THEIR PROMISE IN CANCER TREATMENT , Prospects in Pharmaceutical Sciences: Vol. 14 No. 3 (2016)

<< < 1 2 3 4 5 6 7 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Suchocka, Z. (2003). OBESITY - REASONS AND TREATMENT. Prospects in Pharmaceutical Sciences, 1(1), 1–10. https://doi.org/10.56782/pps.40

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Schonfeld - Warden N., Warden Ch.: Pediatric obesity. An overview of etiology and treatment. Pediatr Clin North Am 1997; 44: 339 - 361. DOI: https://doi.org/10.1016/S0031-3955(05)70480-6

Troiano R.P., Flegal K.M., Kuczmarski R.J., Campbell S.M. Johnson CL.: Overweight prevalence and trends for children and adolescent. The National Health and Nutrition Examination Surveys 1963-1991, Arch Pediatr Adolesc Med 1995; 149, 1085-1091.

Serdula M.K., Irvey D., Coates R.J., Freedman D.S., Williamson D.S., Williamson D.F., Bayers T.: Do obese children become obese adults? A review of literature, Prev Med 1999; 22: 167-77. DOI: https://doi.org/10.1006/pmed.1993.1014

Kłosiewicz - Latoszek L., Pachocka L., Maliszewska K., Grzybek A., Murakowska E., Targosz U., Nowicka G.: Czynniki ryzyka choroby niedokrwiennej serca towarzyszące otyłości. Czynniki Ryzyka 1996; 11: 32 - 37.

Vanhala M.J., Pitkajarvi T.K., Kumpusalo E.A., Tokala J.K.: Obesity type and clustering of insulin resistance- associated cardiovascular risk faktors, in middle- aged men and women. Int J Obes Relat Metab Disord 1998; 22: 369 - 374. DOI: https://doi.org/10.1038/sj.ijo.0800597

Juhan-Vague I., Vague P.: Hypofibrinolisys and insulin - resistance. Diabet Metab 1991; 17: 96 - 100.

Czech A., Bernas M., Tatoń J.: Patofizjologiczne podstawy przechodzenia otyłości w cukrzycę typu II. Pol. Tyg. Lek. 1995; Supl 1: 37 - 41.

Cybulska B., Szostak W.B.: Otyłość wisceralna jako czynnik zagrożenia chorobą niedokrwienną serca. Pol. Tyg. Lek. 1995; Supl 1: 43 - 47.

Kielar D.: Molekularne podłoże etiopatogenezy otyłości (cz. I). Czynniki Ryzyka 1995; 9-10: 49 - 54.

Wójcicki J.: Otyłość - jej wpływ na dystrybucję, biotransformację i eliminację leków z organizmu. Czynniki Ryzyka 1994; 3: 18 - 25.

Basedevant A., Le Barzic M., Guy-Grand B.: Otyłość. Medycyna praktyczna. PZWL, Kraków 1993; 25 - 42.

Rywik S., Wągrowska H., Piotrowski W., Broda G.: Epidemiologia otyłości jako czynnika ryzyka chorób układu krążenia. Pol. Tyg. Lek. 1995; Supl 1 : 63 - 67.

Health implications of obesity. National Institutes of Health Consensus Development Conference Statement. Ann Intern Med 1985: 103;147- 151. DOI: https://doi.org/10.7326/0003-4819-103-1-147

Szmatłoch E.: Współistnienie metabolicznych i innych czynników zagrożenia miażdżycą w otyłości. Pol. Tyg. Lek. 1995; Supl 1 : 41 - 42.

Kielar D.: Molekularne podłoże etiopatogenezy otyłości ( cz. II). Czynniki Ryzyka 1995; 11: 26 31.

Basedevant A., Le Barzic M., Guy-Grand B.: Otyłość. Medycyna praktyczna. PZWL, Kraków 1993; 25 - 42.

Bjorntorp P.: Trifty genes and human obesity. Are we chasing ghosts? Lancet 2000; 358, 1006-1008. DOI: https://doi.org/10.1016/S0140-6736(01)06110-4

Breier B.H., Vicker M.H., Ikenasio B.A., Chan K.Y., Wong W.P.S: Fetal programing of appetite and obesity. Mol. Cell. Endocrinol. 2001; 185, 73-79. DOI: https://doi.org/10.1016/S0303-7207(01)00634-7

Świerczyński J., Kochan Z., Karbowska J.: Geny otyłości. Post. Bioch.1997; 43: 174 - 182.

Sakata T.: Histamine receptor and its regulation of energy metabolism. Obes Res 1995; 3 Supl 4: 541 - 548 DOI: https://doi.org/10.1002/j.1550-8528.1995.tb00225.x

Clement K., Vaisse C., Manning B.S., Basdevant A., Guy-Grand B., Ruiz J., Silver K.D., Shuldiner A.R., Froguel P., Strosberg A.D.: Genetic variation in the b3- adrenergic receptor and an increased capacity to gain weigh in patients with morbid obesity. N. Engl. J. Med. 1995; 333: 352 - 354. DOI: https://doi.org/10.1056/NEJM199508103330605

Walston J., Silver K., Bodardus C.: Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the b3- adrenergic receptor gene. N. Engl. J. Med. 1995; 333: 343 - 347. DOI: https://doi.org/10.1056/NEJM199508103330603

Baranowska B.: Zaburzenia neuroendokrynne w otyłości. Pol. Tyg. Lek. 1995; Supl 1: 26 28.

Vanderschneren - Lodeweyckx M.: The effect of simple obesity on growth and growth hormone. Horm Res 1993; 40: 23 - 30. DOI: https://doi.org/10.1159/000183763

Gutin B., Manos T.M.: Physical Activity in the Prevention of Childhood Obesity. Ann NY Acad Sci 1993; 699: 115 1. DOI: https://doi.org/10.1111/j.1749-6632.1993.tb18843.x

Nazar K., Kaciuba - Uściłko H.: Aktywność ruchowa w zapobieganiu i leczeniu otyłości. Pol. Tyg. Lek. 1995; Supl 1: 68 - 69.

Levin B.E.: Metabolic impriting on genetically Predisposed Neural Circuits Perpetuates Obesity. Nutrition 2000; 16:909-915. DOI: https://doi.org/10.1016/S0899-9007(00)00408-1

Białkowska M.:Otyłość wisceralna - diagnostyka, przyczyny, skutki. Czynniki Ryzyka 1994; 3: 34 - 40.

Poskitt E.: Defining childhood obesity: the relative body mass index (BMI). Acta Paediatr 1995, 84:961-2. DOI: https://doi.org/10.1111/j.1651-2227.1995.tb13806.x

Siatka percentylowa BMI: Palczewska I., Niedźwiecka Z., Instytut Matki i Dziecka, Warszawa 1999.

Komorowski J., Pawlikowski M.: Otyłość i jadłowstręt psychczny. w: Zarys Endokrynologii Klinicznej., Ed.: Komorowski J., Pawlikowski M., PZWL, Warszawa 1992; 223 229].

Dokument WHO. Measuring obesity- classification and description of anthropometric data. Copenhagen,WHO Regional Office for Europe Nutrition Unit EUR/ICP/NUT. 1988;125

Tatoń J.: Związki między otyłością i cukrzycą typu 2. Pol Tyg Lek 1995; Supl 1 :56-62.

Troiano R.P., Flegal K.M., Kuczmarski R.J., Campbell S.M., Johnson C.L.: Overweight prevalence and trends for children and adolescent. The National Health and Nutrition Examinations Surveys 1963-1991. Arch Pediatr Adolesc Med 1995;149: 1085-1091. DOI: https://doi.org/10.1001/archpedi.1995.02170230039005

Caroli M., Lagravinese D.: Prevention of obesity. Nutr Res 2002; 22: 221-226. DOI: https://doi.org/10.1016/S0271-5317(01)00364-5

OBESITY - REASONS AND TREATMENT

Zofia Suchocka

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Zofia Suchocka